Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755257 | 0.87 | CRHBP (0.49) | MEN1KMT2AKDM4EMAPTHTT | |
| SCHEMBL15600148 | 0.84 | KMT2A (0.58) | MEN1KMT2AKDM4EMAPTHTT | |
| SCHEMBL24390008 | 0.82 | PKM (0.54) | MEN1KMT2AKDM4EMAPTHTT | |
| SCHEMBL16748719 | 0.82 | PKM (0.57) | MEN1KMT2AKDM4EMAPTHTT | |
| SCHEMBL31294882 | 0.82 | PKM (0.54) | MEN1KMT2AKDM4EMAPTHTT | |
| SCHEMBL5539731 | 0.80 | MEN1 (0.50) | MEN1KMT2AMAPTPKMTP53 | |
| SCHEMBL10381827 | 0.80 | PKM (0.51) | MEN1KMT2AMAPTPKMCNR1 | |
| SCHEMBL13993447 | 0.80 | MEN1 (0.50) | MEN1KMT2AMAPTPKMTP53 | |
| SCHEMBL9028558 | 0.80 | MEN1 (0.50) | MEN1KMT2AMAPTPKMTP53 | |
| SCHEMBL24201847 | 0.80 | MEN1 (0.50) | MEN1KMT2AMAPTPKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-20200190074-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3632910-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0462831-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5462953-A | Benzoxazolyl derivatives useful as 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-10-31 | — | — | US | disclosed |
| US-5364877-A | Antiinflammatory agents, antiallergens | ICI PHARMA (GB) | 1994-11-15 | — | — | US | disclosed |
| US-5278177-A | Enzyme inhibitory | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-11 | — | — | US | disclosed |
| US-5179115-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-12 | — | — | US | disclosed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | MEN1 710/4885KMT2A 15/4885KDM4E 24/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MEN1 3295/4885KMT2A 4267/4885KDM4E 4854/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | MEN1 1261/4885KMT2A 15/4885KDM4E 22/4885 |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | NR1H4, GPBAR1, SLC10A1 | MEN1 1739/4885KMT2A 4170/4885KDM4E 4512/4885 |
| US-20200190074-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | NR1H4, GPBAR1, SLC10A1 | MEN1 1739/4885KMT2A 4170/4885KDM4E 4512/4885 |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | MEN1 312/4885KMT2A 29/4885KDM4E 43/4885 |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, KDM1A, HDAC1 | MEN1 1533/4885KMT2A 14/4885KDM4E 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.